Medical technology company Teleflex has announced the results of several research studies that support the safety and efficacy of the UroLift System.
The UroLift System is designed for men living with enlarged prostate, or benign prostatic hyperplasia (BPH), including people with a range of prostate sizes and/or a median lobe obstruction.
The firm will present the data at the 37th Annual European Association of Urology (EAU) Congress in Amsterdam and virtually to demonstrate the improvement in BPH Symptoms and IPSS Scores.
In five studies, the outcomes from 300 subjects showed lower international prostate symptom score (IPSS) symptom severity after treatment with Prostatic Urethral Lift (PUL).
Of 300 subjects, 79% of them improved their score by three points and 69% moved into lower IPSS grade.
The study compared controlled trial results from BPH6 for patients with modest prostate diameters with MedLift for individuals with obstructed median lobes to investigate PUL outcomes in various gland sizes and shapes.
All groups showed considerable and ongoing IPSS improvement at 24 months.
Teleflex said that the study found that compared to BPH patients treated with the UroLift System, those who underwent more invasive surgical treatments had considerably greater post-surgical drug utilisation.
Teleflex Global Clinical and Scientific Operations vice president Jacqueline Welch said: “Extensive research has shown that the UroLift System can consistently and rapidly improve BPH symptoms for our patients.
“The research conducted by some of the world’s foremost BPH experts and presented at this year’s EAU continues to build the body of support, which may help a broad population of men potentially avoid more invasive surgery.”
The UroLift System is a minimally invasive treatment for lower urinary tract symptoms which can be done without heating, cutting, destruction of, or removing prostate tissue.
In May this year, the company announced the commercial availability of its UroLift 2 System and UroLift ATC System in the US.
